Cancers & treatments·Regimen libraryFirst line

Venetoclax + azacitidine

Checked 2026-09-09

Newly diagnosed AML unfit for intensive chemotherapy

One cycle

every 28 days

28-day cycle, until progressionSubcutaneousOral Daily oral course

Components

Drug	Dose	Route	Days	Note
Azacitidine Small-molecule hypomethylating agent (cytotoxic)	75 mg/m²	SC	D1-7
Venetoclax Small-molecule BCL-2 inhibitor	100 mg day 1, 200 mg day 2, then 400 mg daily (cycle 1 ramp-up); often days 1-21 from cycle 2	Oral	D1-28

Cycles

until progression

28-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

Azole antifungals: reduce venetoclax to 100 mg (posaconazole) or 200 mg (voriconazole).
Marrow at day 21-28 of cycle 1; delay the next cycle if hypoplastic and in remission.

Used in

Acute myeloid leukaemia Myelodysplastic syndromes / neoplasms (MDS)

Trials

VIALE-A

Products

AzacitidineVenetoclax

Source

VIALE-A, NEJM 2020

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

7+3 (cytarabine + anthracycline) ± midostaurin

Fit adults with newly diagnosed AML; midostaurin for FLT3-mutated disease (quizartinib for FLT3-ITD)

every 28 days × 1-2

ATRA + arsenic trioxide

Low or intermediate-risk acute promyelocytic leukaemia (WBC 10 × 10⁹/L or less)

every 28 days

ADE (cytarabine, daunorubicin, etoposide)

Induction for younger adults with acute myeloid leukaemia in the UK MRC and NCRI trials; an alternative to 7+3

every 28 days × 2

All regimens ATRA + arsenic trioxide →